PDF(Pubmed)
Abstract：
UNASSIGNED: This retrospective study was to understand the clinico-epidemiologic and therapeutic aspects of pemphigus patients attending our clinic.
UNASSIGNED: We analyzed charts of 143 (M: F; 51:92) pemphigus patients having variable severity recorded between 2009 and 2019. Therapies were customized based on patient\'s age, disease severity, comorbidities, compliance prospects, and affordability. The patients were monitored monthly and as needed for therapeutic outcome in terms of disease control, reduced hospitalization, remission/relapse, and drug toxicity.
UNASSIGNED: These patients were aged 15 to 86 years, the majority, 68 (47.5%), was 41 to 60 years of age. The pemphigus vulgaris in 83.9% patients was the commonest variant. Treatment regimens were; dexamethasone-cyclophosphamide-pulse (DCP) therapy in 51.2%, dexamethasone-azathioprine-pulse (DAP) therapy in 11%, dexamethasone-pulse (DP) therapy in 5.5%, rituximab in 24.4%, IVIg in 5.5% patients, and oral corticosteroids with or without adjuvant. Remission occurred after 2-17 (mean 5.8) DCP doses; 14 and 7 patients achieved remission for ≥2 y and ≥5 y, respectively. Rituximab was effective to treat both new and relapsed cases (n = 31). Additional treatment with another adjuvant prolonged remission in seven patients relapsed 12-16 months after treatment with rituximab alone. Overall, oral corticosteroids alone and DAP therapy showed unsatisfactory response. Adverse effects seen in 41.9% of patients were mainly corticosteroids related.
UNASSIGNED: The overall clinico-epidemiologic spectrum of pemphigus and therapeutic efficacy of DCP, DAP, or corticosteroids in this study was in sync with the literature. Combining rituximab and corticosteroids plus an immunomodulator initially (phase-1), followed by immunomodulator alone for one year (phase-2) will improve long-term (phase-3) therapeutic outcome. IVIg was effectively useful in patients with concurrent infections.
UNASSIGNED: We analyzed charts of 143 (M: F; 51:92) pemphigus patients having variable severity recorded between 2009 and 2019. Therapies were customized based on patient\'s age, disease severity, comorbidities, compliance prospects, and affordability. The patients were monitored monthly and as needed for therapeutic outcome in terms of disease control, reduced hospitalization, remission/relapse, and drug toxicity.
UNASSIGNED: These patients were aged 15 to 86 years, the majority, 68 (47.5%), was 41 to 60 years of age. The pemphigus vulgaris in 83.9% patients was the commonest variant. Treatment regimens were; dexamethasone-cyclophosphamide-pulse (DCP) therapy in 51.2%, dexamethasone-azathioprine-pulse (DAP) therapy in 11%, dexamethasone-pulse (DP) therapy in 5.5%, rituximab in 24.4%, IVIg in 5.5% patients, and oral corticosteroids with or without adjuvant. Remission occurred after 2-17 (mean 5.8) DCP doses; 14 and 7 patients achieved remission for ≥2 y and ≥5 y, respectively. Rituximab was effective to treat both new and relapsed cases (n = 31). Additional treatment with another adjuvant prolonged remission in seven patients relapsed 12-16 months after treatment with rituximab alone. Overall, oral corticosteroids alone and DAP therapy showed unsatisfactory response. Adverse effects seen in 41.9% of patients were mainly corticosteroids related.
UNASSIGNED: The overall clinico-epidemiologic spectrum of pemphigus and therapeutic efficacy of DCP, DAP, or corticosteroids in this study was in sync with the literature. Combining rituximab and corticosteroids plus an immunomodulator initially (phase-1), followed by immunomodulator alone for one year (phase-2) will improve long-term (phase-3) therapeutic outcome. IVIg was effectively useful in patients with concurrent infections.
摘要：
未经评估：这项回顾性研究旨在了解到我们诊所就诊的天疱疮患者的临床流行病学和治疗方面。
UNASSIGNED：我们分析了2009年至2019年间记录的143例（M：F;51：92）天疱疮患者的图表。治疗是根据患者的年龄定制的，疾病严重程度,合并症,合规前景，和负担能力。每月对患者进行监测，并根据需要在疾病控制方面获得治疗结果，减少住院，缓解/复发，和药物毒性。
未经证实：这些患者年龄为15至86岁，大多数,68（47.5%），年龄41至60岁。83.9%的寻常型天疱疮是最常见的变异型。治疗方案为；地塞米松-环磷酰胺脉冲（DCP）治疗51.2％，地塞米松-硫唑嘌呤脉冲（DAP）治疗11％，地塞米松脉冲（DP）治疗5.5％，利妥昔单抗占24.4%，5.5％的患者IVIg，和口服皮质类固醇，有或没有佐剂。缓解发生在2-17次（平均5.8次）DCP剂量后；14和7例患者在≥2年和≥5年时达到缓解，分别。利妥昔单抗可有效治疗新发和复发病例（n=31）。7例患者在单独使用利妥昔单抗治疗后12-16个月复发，另一种辅助治疗延长了缓解时间。总的来说,单独口服皮质类固醇和DAP治疗的疗效不理想.41.9%的患者不良反应主要与糖皮质激素有关。
未经评估：天疱疮的总体临床流行病学谱和DCP的治疗效果，DAP,或皮质类固醇在这项研究中与文献同步。利妥昔单抗和皮质类固醇联合免疫调节剂初始（1期），随后单独使用免疫调节剂1年(第2期)将改善长期(第3期)治疗结果.IVIg对并发感染的患者有效。
UNASSIGNED：我们分析了2009年至2019年间记录的143例（M：F;51：92）天疱疮患者的图表。治疗是根据患者的年龄定制的，疾病严重程度,合并症,合规前景，和负担能力。每月对患者进行监测，并根据需要在疾病控制方面获得治疗结果，减少住院，缓解/复发，和药物毒性。
未经证实：这些患者年龄为15至86岁，大多数,68（47.5%），年龄41至60岁。83.9%的寻常型天疱疮是最常见的变异型。治疗方案为；地塞米松-环磷酰胺脉冲（DCP）治疗51.2％，地塞米松-硫唑嘌呤脉冲（DAP）治疗11％，地塞米松脉冲（DP）治疗5.5％，利妥昔单抗占24.4%，5.5％的患者IVIg，和口服皮质类固醇，有或没有佐剂。缓解发生在2-17次（平均5.8次）DCP剂量后；14和7例患者在≥2年和≥5年时达到缓解，分别。利妥昔单抗可有效治疗新发和复发病例（n=31）。7例患者在单独使用利妥昔单抗治疗后12-16个月复发，另一种辅助治疗延长了缓解时间。总的来说,单独口服皮质类固醇和DAP治疗的疗效不理想.41.9%的患者不良反应主要与糖皮质激素有关。
未经评估：天疱疮的总体临床流行病学谱和DCP的治疗效果，DAP,或皮质类固醇在这项研究中与文献同步。利妥昔单抗和皮质类固醇联合免疫调节剂初始（1期），随后单独使用免疫调节剂1年(第2期)将改善长期(第3期)治疗结果.IVIg对并发感染的患者有效。
